Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis.

Cellular oncology (Dordrecht, Netherlands) - 1 Feb 2025

Han Jung-Min, Oh Kyu-Young, Choi Su-Jung, Lee Won-Woo, Jin Bo-Hwan, Kim Ji-Hoon, Yu Hyun-Ju, Kim Ryan Jin Young, Yoon Hye-Jung, Lee Jae-Il, Hong Seong-Doo, Cho Sung-Dae

Abstract excerpt

PURPOSE: This study investigates the role and effectiveness of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in oral cancer, focusing on the clinical relevance of EGFR and myeloid cell leukemia-1 (Mcl-1) in head and neck cancers (HNCs). It aims to explore the molecular mechanism of afatinib, a TKI, in treating human oral cancer. METHODS: We conducted an in silico analysis using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Mouth Neoplasms

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Quinazolines

Share to TOR Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38888847
DOI: 10.1007/s13402-024-00962-6
PMCID: PMC11850456

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis.PMID 38888847Read ↗

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axisSemantic proximity Read ↗

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Semantic proximity Read ↗

Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastomaSemantic proximity Read ↗

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.Semantic proximity Read ↗

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.Semantic proximity Read ↗

[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].Semantic proximity Read ↗

Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivoSemantic proximity Read ↗

Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach.Semantic proximity Read ↗

Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.Semantic proximity Read ↗

Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.Semantic proximity Read ↗

Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.Semantic proximity Read ↗

Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.